CAR-T cell therapy from cord blood for lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a confirmed diagnosis of lupus that is active (with a score of 8 or higher on a lupus activity scale, or certain severe symptoms).
- You have tried at least two standard lupus treatments for 3 months or more without success.
- Your major organs (like bone marrow, liver, kidneys, heart) are working well enough as shown by recent blood tests and medical exams.
- You are not pregnant, plan to become pregnant, or breastfeeding, and you agree to use birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy that targets a specific type of immune cell (B cell) to calm the overactive immune response in lupus, which may help reduce symptoms. It is for people with active lupus that has not responded well to other treatments.
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new type of immune cell therapy (CAR T-cells from umbilical cord blood) for people with certain autoimmune diseases that haven't responded to standard treatments. It aims to see if targeting two proteins (CD19 and BCMA) can help calm the overactive immune system.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.